Publication

Video

Supplements and Featured Publications
Novel Emerging Therapies in Relapsed/Refractory AML
Volume 1
Issue 1

Dr. DeAngelo on the Exploration of Uproleselan Plus Chemotherapy in R/R AML

Daniel J. DeAngelo, MD, PhD, discusses the exploration of uproleselan plus chemotherapy in relapsed/refractory acute myeloid leukemia.

Daniel J. DeAngelo, MD, PhD, associate professor of Medicine, Harvard Medical School, physician, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the exploration of uproleselan (GMI-1271) plus chemotherapy in relapsed/refractory acute myeloid leukemia.

A phase 3 study (NCT03616470) is evaluating the efficacy and safety of uproleselan plus chemotherapy, vs placebo plus chemotherapy. The primary end point of the study is overall survival.

Eligible patients for this trial could be in first or second relapse after failing on an anthracycline regimen, DeAngelo says. Additionally, the study will utilize 2 different chemotherapy backbones of mitoxantrone, etoposide, and cytarabine (MEC), or fludarabine, cytarabine and idarubicin, DeAngelo explains. Notably, the MEC backbone was studied with uproleselan in a phase 1/2 trial (NCT02306291). Granulocyte colony stimulating factor (G-CSF) will not be used in the trial since safety concerns of G-CSF and E-selectin have not been thoroughly studied, DeAngelo notes.

Despite challenges of the COVID-19 pandemic, the phase 3 trial has met its accrual, DeAngelo continues. Investigators are waiting for the appropriate number of events before the study is unblinded, DeAngelo concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP